BRPI9912896B8 - ß-l-2' -desoxinucleosídeos para tratamento de hepatite b - Google Patents

ß-l-2' -desoxinucleosídeos para tratamento de hepatite b

Info

Publication number
BRPI9912896B8
BRPI9912896B8 BRPI9912896A BR9912896A BRPI9912896B8 BR PI9912896 B8 BRPI9912896 B8 BR PI9912896B8 BR PI9912896 A BRPI9912896 A BR PI9912896A BR 9912896 A BR9912896 A BR 9912896A BR PI9912896 B8 BRPI9912896 B8 BR PI9912896B8
Authority
BR
Brazil
Prior art keywords
dioxy
nucleotide
hepatitis
pentafuran
erythopentafuran
Prior art date
Application number
BRPI9912896A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9912896A (pt
BRPI9912896B1 (pt
Inventor
Gosselin Gilles
Imbach Jean-Louis
L Bryant Martin
Original Assignee
Centre Nat Rech Scient
Idenix Cayman Ltd
Idenix Pharmaceuticals Inc
Luniversite Montpellier Ii
Novartis Ag
Novirio Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26791121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9912896(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre Nat Rech Scient, Idenix Cayman Ltd, Idenix Pharmaceuticals Inc, Luniversite Montpellier Ii, Novartis Ag, Novirio Pharmaceuticals Ltd filed Critical Centre Nat Rech Scient
Publication of BR9912896A publication Critical patent/BR9912896A/pt
Publication of BRPI9912896B1 publication Critical patent/BRPI9912896B1/pt
Publication of BRPI9912896B8 publication Critical patent/BRPI9912896B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI9912896A 1998-08-10 1999-08-10 ß-l-2' -desoxinucleosídeos para tratamento de hepatite b BRPI9912896B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9611098P 1998-08-10 1998-08-10
US13135299P 1999-04-28 1999-04-28
PCT/US1999/018149 WO2000009531A2 (en) 1998-08-10 1999-08-10 β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B

Publications (3)

Publication Number Publication Date
BR9912896A BR9912896A (pt) 2002-02-13
BRPI9912896B1 BRPI9912896B1 (pt) 2016-08-09
BRPI9912896B8 true BRPI9912896B8 (pt) 2021-05-25

Family

ID=26791121

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9912896A BRPI9912896B8 (pt) 1998-08-10 1999-08-10 ß-l-2' -desoxinucleosídeos para tratamento de hepatite b

Country Status (21)

Country Link
US (5) US6395716B1 (cg-RX-API-DMAC7.html)
EP (2) EP2415776B1 (cg-RX-API-DMAC7.html)
JP (2) JP4294870B2 (cg-RX-API-DMAC7.html)
KR (4) KR100634342B1 (cg-RX-API-DMAC7.html)
CN (3) CN100482236C (cg-RX-API-DMAC7.html)
AT (1) ATE313550T1 (cg-RX-API-DMAC7.html)
AU (1) AU5475799A (cg-RX-API-DMAC7.html)
BR (1) BRPI9912896B8 (cg-RX-API-DMAC7.html)
CA (1) CA2340156C (cg-RX-API-DMAC7.html)
CY (2) CY2007017I1 (cg-RX-API-DMAC7.html)
DE (2) DE122007000062I1 (cg-RX-API-DMAC7.html)
DK (3) DK1104436T3 (cg-RX-API-DMAC7.html)
ES (3) ES2531928T3 (cg-RX-API-DMAC7.html)
FR (1) FR07C0046I2 (cg-RX-API-DMAC7.html)
LU (1) LU91348I2 (cg-RX-API-DMAC7.html)
MX (1) MXPA01001507A (cg-RX-API-DMAC7.html)
NL (1) NL300286I2 (cg-RX-API-DMAC7.html)
PT (2) PT1431304E (cg-RX-API-DMAC7.html)
RU (1) RU2424016C2 (cg-RX-API-DMAC7.html)
SG (1) SG132498A1 (cg-RX-API-DMAC7.html)
WO (1) WO2000009531A2 (cg-RX-API-DMAC7.html)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4413996B2 (ja) * 1995-06-07 2010-02-10 エモリー・ユニバーシティ 抗ｂ型肝炎ウィルス活性を有するヌクレオシド
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
EP2415776B1 (en) 1998-08-10 2016-05-25 Novartis AG Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B
MXPA02004779A (es) * 1999-11-12 2004-07-01 Pharmasset Ltd Sintesis de 2'-desoxi-l-nucleosidos.
EP1634888A3 (en) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
EE05442B1 (et) * 2000-02-29 2011-08-15 Bristol-Myers Squibb Company V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks
AU2001245575A1 (en) * 2000-03-09 2001-09-17 Videoshare, Inc. Sharing a streaming video
US6822089B1 (en) * 2000-03-29 2004-11-23 Isis Pharmaceuticals, Inc. Preparation of deoxynucleosides
ES2319732T3 (es) 2000-04-13 2009-05-12 Pharmasset, Inc. Derivados de nucleosido 3'- o 2'-hidroximetilo sustituido para el tratamiento de infecciones virales.
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) * 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
US6787526B1 (en) * 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
ATE275406T1 (de) 2000-05-26 2004-09-15 Idenix Cayman Ltd Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden
MY141594A (en) * 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
CN100368422C (zh) * 2000-11-29 2008-02-13 三井化学株式会社 L-核酸衍生物及其合成方法
CN101250194B (zh) * 2000-11-29 2011-05-04 三井化学株式会社 L-核酸衍生物及其合成方法
AU2002360697B2 (en) 2001-12-20 2009-04-23 Beth Israel Deaconess Medical Center Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
CA2470521A1 (en) * 2001-12-21 2003-07-10 Micrologix Biotech Inc. Anti-viral 7-deaza l-nucleosides
AU2003217863B9 (en) * 2002-02-28 2009-10-29 Biota Scientific Management Pty Ltd Nucleotide mimics and their prodrugs
US20060084627A1 (en) * 2002-06-27 2006-04-20 Medivir Ab Synergistic interaction of abacavir and alovudine
JP2005533817A (ja) 2002-06-28 2005-11-10 イデニクス（ケイマン）リミテツド フラビウィルス科ウィルス感染治療用の修飾２′および３′−ヌクレオシドプロドラッグ
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
JP2005533824A (ja) * 2002-06-28 2005-11-10 イデニクス（ケイマン）リミテツド フラビウイルス科感染の治療のための２’−ｃ−メチル−３’−ｏ−ｌ−バリンエステルリボフラノシルシチジン
RS114104A (sr) 2002-06-28 2007-02-05 Idenix (Cayman) Limited, 2'i 3'-nukleozidni prolekovi za lečenje flaviviridae infekcija
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
US7186700B2 (en) * 2002-09-13 2007-03-06 Idenix Pharmaceuticals, Inc. β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
EP1556393B1 (en) 2002-10-31 2013-12-25 Metabasis Therapeutics, Inc. Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs
US7824851B2 (en) * 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
EP1585529A4 (en) * 2002-12-12 2008-05-28 Idenix Cayman Ltd PROCESS FOR PREPARING 2'-BRANCHED NUCLEOSIDES
US7582748B2 (en) 2003-03-20 2009-09-01 Microbiologica Quimica E Farmaceutical Ltd. Methods of manufacture of 2′-deoxy-β-L-nucleosides
WO2004096149A2 (en) * 2003-04-28 2004-11-11 Idenix (Cayman) Limited Industrially scalable nucleoside synthesis
WO2004096197A2 (en) * 2003-05-02 2004-11-11 Universita Degli Studi Di Cagliari 5-aza-7-deazapurine nucleosides for treating flaviviridae
ES2586668T5 (es) 2003-05-30 2024-11-12 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
KR20060035652A (ko) 2003-06-30 2006-04-26 이데닉스 (케이만) 리미티드 β-Ｌ-2-데옥시 뉴클레오시드의 합성
CN1315863C (zh) * 2003-12-12 2007-05-16 河南省科学院质量检验与分析测试研究中心 β－L－2'－脱氧－核苷衍生物、其合成方法及其药物用途
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CA2634749C (en) * 2005-12-23 2014-08-19 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
KR101059593B1 (ko) 2006-04-11 2011-08-25 노파르티스 아게 Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090082306A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telbivudine
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
BRPI0923815A2 (pt) 2008-12-23 2015-07-14 Pharmasset Inc Síntese de nucleosídeos de purina
EA019341B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Фосфорамидаты нуклеозидов
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
CA2781054A1 (en) * 2009-11-16 2011-05-19 Chung K. Chu 2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections
LT2609923T (lt) 2010-03-31 2017-09-11 Gilead Pharmasset Llc (s)-izopropilo 2-(((s)-(perfluorfenoksi)(fenoksi)fosforil)amino)-propanoato kristalinimo būdas
US9011833B2 (en) 2010-10-08 2015-04-21 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
CN102649788B (zh) * 2011-02-28 2015-03-25 四川大学 β-L-2’-脱氧-胸腺嘧啶核苷衍生物及其制备方法和用途
CA2840242C (en) 2011-09-16 2019-03-26 Gilead Sciences, Inc. Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP3650013A1 (en) 2013-01-31 2020-05-13 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
SI3038601T1 (sl) 2013-08-27 2020-07-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
CA2937548C (en) 2014-02-13 2022-10-25 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
RU2020126177A (ru) 2018-01-09 2022-02-10 Лиганд Фармасьютикалз, Инк. Ацетальные соединения и их терапевтическое применение
CN110680806A (zh) * 2018-07-04 2020-01-14 郑州泰丰制药有限公司 一种替比夫定颗粒的制备方法
CN108570078A (zh) * 2018-07-18 2018-09-25 荆门医药工业技术研究院 一种制备1-O-乙酰基-2,3,5-三-O-苯甲酰基-β-D-呋喃核糖的方法
CN114133398B (zh) * 2021-12-31 2022-11-22 中南民族大学 氨基酸取代的阿昔洛韦类三环核苷衍生物及其合成方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB875971A (en) 1959-01-14 1961-08-30 Hoffmann La Roche A process for the manufacture of uridine and thymidine derivatives and novel compounds concerned therein
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4916122A (en) 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5190926A (en) 1987-01-28 1993-03-02 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
EP0380558A4 (en) 1987-09-22 1991-07-31 The Regents Of The University Of California Liposomal nucleoside analogues for treating aids
DE3855513T2 (de) 1987-10-28 1997-01-09 Pro Neuron Inc Acyl deoxyribonukleosid-derivate und deren verwendungen
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
JP2675864B2 (ja) 1988-07-05 1997-11-12 キヤノン株式会社 被記録材及びこれを用いたインクジェット記録方法
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
WO1991018914A1 (en) 1990-05-29 1991-12-12 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
DE69115694T2 (de) 1990-06-13 1996-10-17 Arnold Newton Mass. Glazier Phosphorylierte prodrugs
ATE133233T1 (de) 1990-07-12 1996-02-15 G Drill Ab Gesteinsbohrgerät mit hydraulischem antrieb im bohrloch
DE10399025I2 (de) * 1990-09-14 2007-11-08 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
IT1246983B (it) 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
SK279542B6 (sk) 1991-03-06 1998-12-02 The Wellcome Foundation Limited U
US5220003A (en) 1991-03-29 1993-06-15 The Regents Of The University Of California Process for the synthesis of 2',3'-dideoxynucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
AU668873B2 (en) 1991-07-12 1996-05-23 Chimerix, Inc. Antiviral liponucleosides: treatment of hepatitis B
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
CA2157902A1 (en) * 1993-03-10 1994-09-15 Christopher Douglas Valiant Black Tumour targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
JP3693357B2 (ja) 1993-04-09 2005-09-07 峯郎 実吉 逆転写酵素阻害剤
EP0746319A4 (en) 1993-05-12 1997-11-05 Karl Y Hostetler ACYCLOVIR DERIVATIVES FOR TOPICAL USE
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
WO1995007086A1 (en) 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
WO1996011204A1 (de) * 1994-10-07 1996-04-18 Max-Delbrück-Centrum für Molekulare Medizin NEUE β-L-NUCLEOSIDE UND IHRE VERWENDUNG
US5559101A (en) 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
JP4413996B2 (ja) * 1995-06-07 2010-02-10 エモリー・ユニバーシティ 抗ｂ型肝炎ウィルス活性を有するヌクレオシド
US6025335A (en) * 1995-09-21 2000-02-15 Lipitek International, Inc. L-Nucleoside Dimer Compounds and therapeutic uses
CA2322494A1 (en) 1998-03-11 1999-09-16 Annette M. Gero Novel nucleoside analogs and uses in treating disease
WO1999066936A1 (en) 1998-06-24 1999-12-29 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
EP2415776B1 (en) * 1998-08-10 2016-05-25 Novartis AG Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) * 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
KR20080021797A (ko) * 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
ATE275406T1 (de) * 2000-05-26 2004-09-15 Idenix Cayman Ltd Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden

Also Published As

Publication number Publication date
CN1478483A (zh) 2004-03-03
BR9912896A (pt) 2002-02-13
CN1606983A (zh) 2005-04-20
JP2002522552A (ja) 2002-07-23
KR20050062664A (ko) 2005-06-23
CN100387237C (zh) 2008-05-14
KR20010072392A (ko) 2001-07-31
CA2340156A1 (en) 2000-02-24
JP2007269798A (ja) 2007-10-18
PT1431304E (pt) 2015-03-09
KR100691737B1 (ko) 2007-03-12
KR100634342B1 (ko) 2006-10-16
HK1097776A1 (en) 2007-07-06
HK1034083A1 (en) 2001-10-12
AU5475799A (en) 2000-03-06
DK1431304T3 (en) 2015-03-02
MXPA01001507A (es) 2003-09-10
US20030225028A1 (en) 2003-12-04
EP2415776A1 (en) 2012-02-08
FR07C0046I1 (cg-RX-API-DMAC7.html) 2007-10-26
US20060084624A1 (en) 2006-04-20
CA2340156C (en) 2007-10-23
DE122007000062I1 (de) 2007-12-20
WO2000009531A2 (en) 2000-02-24
EP1104436A2 (en) 2001-06-06
CN100482236C (zh) 2009-04-29
US7304043B2 (en) 2007-12-04
EP1104436B1 (en) 2005-12-21
LU91348I2 (fr) 2007-09-18
KR100702230B1 (ko) 2007-04-03
ES2255295T3 (es) 2006-06-16
DK1104436T3 (da) 2006-04-03
PT2415776T (pt) 2016-07-07
WO2000009531A3 (en) 2000-06-15
EP2415776B1 (en) 2016-05-25
HK1111913A1 (en) 2008-08-22
CN1320128A (zh) 2001-10-31
CY2007017I2 (el) 2009-11-04
US6569837B1 (en) 2003-05-27
CN1257912C (zh) 2006-05-31
DE69929060T2 (de) 2006-08-31
LU91348I9 (cg-RX-API-DMAC7.html) 2018-12-31
US20080064655A1 (en) 2008-03-13
KR100568035B1 (ko) 2006-04-07
ATE313550T1 (de) 2006-01-15
CY2007017I1 (el) 2009-11-04
DK2415776T3 (en) 2016-07-04
NL300286I1 (nl) 2007-10-01
US6395716B1 (en) 2002-05-28
CY1116988T1 (el) 2017-04-05
FR07C0046I2 (fr) 2008-05-09
NL300286I2 (nl) 2008-01-02
JP4294870B2 (ja) 2009-07-15
ES2579903T3 (es) 2016-08-17
RU2424016C2 (ru) 2011-07-20
KR20060038483A (ko) 2006-05-03
ES2531928T3 (es) 2015-03-20
DE69929060D1 (de) 2006-01-26
KR20060035817A (ko) 2006-04-26
RU2006147216A (ru) 2008-07-10
BRPI9912896B1 (pt) 2016-08-09
SG132498A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
BRPI9912896B8 (pt) ß-l-2' -desoxinucleosídeos para tratamento de hepatite b
JP2004513070A5 (cg-RX-API-DMAC7.html)
AR035711A1 (es) Prodrogas 3' de 2'-desoxi-beta-l-nucleosidos; sus composiciones farmaceuticas; metodo para el tratamiento o profilaxis de una infeccion del virus de la hepatitis b y sus usos para la manufactura de composiciones farmaceuticas
Meier cycloSal-pronucleotides-design of chemical Trojan horses
Schultz Prodrugs of biologically active phosphate esters
US5362732A (en) Boronated compounds
BR0111127A (pt) Métodos e composições para tratamento do vìrus de hepatite c
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
BR0009378A (pt) Métodos de tratamento de leucemia
TR200201001T2 (tr) Pürin türevleri
KR970701198A (ko) 3'-치환 뉴클레오시드 유도체(3'-substituted nucleoside derivative)
KR870006900A (ko) 항바이러스 조성물
BR9915555A (pt) Composto, composição e uso de ß - l- (2' ou 3' -azido) - 2', 3' -didesóxi -5-flúor citosina para o tratamento de infecção por vìrus de hepatite b
ATE287414T1 (de) Antitumorale uridinderivate
DE69031340D1 (de) 3'-azido-2',3'-dideoxy-5-methylcytidin enthaltende antivirale zusammensetzungen
BRPI0409088A (pt) composições farmacêuticas para administração intranasal de ácido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0]non-1(7)-en-2-il)alquil]-fosfÈnico e derivados e métodos de uso dos mesmos
Périgaud et al. The S-acyl-2-thioethyl pronucleotide approach applied to acyclovir: part I. Synthesis and in vitro anti-hepatitis B virus activity of bis (S-acyl-2-thioethyl) phosphotriester derivatives of acyclovir
CY1117836T1 (el) Βητα-l-2'-δεοξυ-νουκλεοσιδια για την θεραπεια ηπατιτιδας β
DE69930678D1 (de) Azidoderivate von beta-l-2'-nukleosiden zur hiv-infektionsbehandlung
RU2001106651A (ru) Бета-l-2 - дезокси-нуклеотиды для лечения гепатита в
JP2003501391A (ja) 細菌毒力を制御するためのメチル化のモジュレーター
KR890001560A (ko) 항바이어러스 조성물
RU2001115094A (ru) Нуклеозиды, обладающие активностью против вируса гепатита в
TH83125A (th) อนุพันธ์เนยูรามินิค แอซิด การเตรียมของมันและการใช้ประโยชน์ของมันทางการแพทย์
TH34789B (th) อนุพันธ์เนยูรามินิค แอซิด การเตรียมของมันและการใช้ประโยชน์ของมันทางการแพทย์

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR)

Free format text: ALTERADO DE: NOVIRIO PHARMACEUTICALS LIMITED

B25A Requested transfer of rights approved

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR)

Free format text: TRANSFERIDO DE: IDENIX PHARMACEUTICALS, INC.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR)

B25A Requested transfer of rights approved

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/08/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/08/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 10/08/2019